Health Affairs Scholar
August 27, 2026
Danielle R Adams, Morgan Hartman, Lisa Gong et al.
Abstract Introduction Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what prospective clients with psychiatric histories encounter when contacting service centers, including how staff communicate about safety, eligibility, and cost. Methods We conducted a mystery shopper study of 26 licensed service centers in Oregon...
The Journal of Clinical Psychiatry
June 10, 2026
Jacob T. Steinle, Suraj Shankar, Joshua S. Siegel et al.
Background: Current drug policy debates often center on whether hallucinogen-related hospital admissions indicate a causal relationship with psychosis. This study examines the extent to which observed associations between hallucinogen use and psychosis are mediated by preexisting psychiatric conditions, providing important evidence for psychedelic policy formulation. Methods: We conducted a...
Nat Hum Behav
February 24, 2025
Ginger E. Nicol, Danielle R Adams, Eric J Lenze et al.
4 citations
There is a push to shrink the anticipated 17-year research-to-practice gap for psychedelic-assisted therapy (PAT), offering precarious hope to those with disabling mental health conditions. However, numerous questions regarding how PAT works, how well it works, for whom and in what context remain. Substantial changes to current systems of care, including regulatory approvals, clinical training...
Translational Behavioral Medicine
October 17, 2024
Danielle R Adams, Heidi Allen, Ginger E. Nicol et al.
7 citations
Abstract Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the potential to produce rapid therapeutic effects when paired with psychotherapy. Randomized clinical trials of psychedelic-assisted psychotherapy (PAT) have shown promising results for post-traumatic stress disorder (PTSD), depression, and substance use...